A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients

Several clinical and biological features, like cytogenetic and molecular alterations, may predict the short- and long-term outcomes in patients with AML treated with intensive approaches [1,2]. However, the main prognostic factor after front-line induction treatment is the leukemic cell sensitivity to the chemotherapy itself (i.e, to achieve or not a first CR as well as the quality and duration of the CR) [3,4]. In order to predict response to chemotherapy, many individualized sensitivity and resistance assays have been deployed for detecting ex vivo drug-inducible cell death.

Source: Leukemia Research - November 13, 2018 Category: Hematology Authors: David Mart ínez-Cuadrón, Cristina Gil, Josefina Serrano, Gabriela Rodríguez, Jaime Pérez-Oteyza, Raimundo García-Boyero, Santiago Jiménez-Bravo, Susana Vives, María Belén Vidriales, Esperanza Lavilla, José A. Pérez-Simón, Mar Tormo, Mercedes Co Source Type: research